Terrence R. Burke Jr., Ph.D.
Dr. Burke utilizes bioorganic and medicinal chemistry to prepare new biologically-active molecules, with an emphasis on peptides and peptide mimetics. His recent work has dealt with the development of inhibitors directed against phosphor-dependent protein-protein interactions, HIV-1 integrase and protein-tyrosine phosphatases. He is also engaged in developing antibody-drug conjugates. Link to additional information about Dr. Burke's research.
1) bioorganic and medicinal chemistry, 2) peptide and peptide mimetic chemistry, 3) inhibitors of phospho-dependent protein-protein interactions (PPIs), 4) HIV integrase inhibitors,
5) antibody-drug conjugates (ADCs), 6) protein-tyrosine phosphatase inhibitors
Bioorganic Medicinal Chemistry and the Modulation of Kinase-Dependent Signal Transduction
Pharmacological agents are being developed to modulate phospho-dependent cell signaling. Historically, our emphasis in this area has been on inhibitors of phosphotyrosyl (pTyr)-dependent binding interactions, which are mediated by src homology 2 (SH2) domains and on protein-tyrosine phosphatase (PTP) inhibitors. More recently, our efforts have focused on developing polo-like kinase 1 (Plk1) polo-box domain (PBD)-binding inhibitors. Central to all these efforts is the development phosphoamino acid surrogates that afford either increased stability toward enzymatic degradation, increased affinity or increased cellular uptake.
In the SH2 domain area, we have collaborated with Dr. Donald Bottaro (CCR, NCI) to develop cell-permeable growth factor receptor-bound 2 (Grb2) antagonists as potential new therapeutics for a variety of erbB-2- and MET-dependent cancers, including breast cancer. For this work, we designed peptidomimetics as conformationally constrained analogs of natural Grb2 SH2 domain-bound pTyr-containing peptides. In related research, a series of new pTyr-mimicking amino acid analogs were prepared to enhance cell permeability.
In the phosphatase area, our recent efforts have concerned the development of inhibitors of the Yersinia pestis phosphatase, YopH, which is a PTP required for infectivity of this potential bioterrorism agent. This work is being conducted as a collaboration with Drs. David Waugh (CCR, NCI) and Robert Ulrich (USAMRIID). Here we have used an oxime library-based approach guided by X-ray co-crystal structures of our inhibitors bound to YopH. In the Plk1 area, we currently have a significant effort underway to develop Plk1 PBD-binding antagonists. This work is being done in collaboration with Dr. Kyung Lee (CCR, NCI). Starting from a pentamer phosphothreonine (pThr) peptide derived from a cognate Plk1 substrate, we are designing and synthesizing peptides and peptide mimetics that contain modified amino acid analogs. We have arrived at agents with extremely high PBD-binding affinity, that have the ability to block division of cancer cells in culture. The goal of this work is to achieve compounds that can exert potent anticancer effects in animal tumor models.
In separate work, inhibitors of HIV integrase are being developed as potential anti-AIDS drugs. Lead inhibitor structures have initially been derived from several sources, including three-dimensional pharmacophore searching of the more than 250,000 compounds contained within the NCI's chemical repository. Promising compounds have been systematically explored through chemical synthesis of analogs to determine structure-activity relationships (SAR) responsible for integrase inhibition. Information generated in this fashion has been applied to the design and preparation of new analogs having higher potency, reduced collateral cytotoxicity, and greater antiviral protective effects in HIV-infected cells.
In collaboration with Drs. Steve Hughes (CCR, NCI) and Yves Pommier (CCR, NCI) we have recently developed non-cytotoxic agents that exhibit anti-viral efficacies in cell culture models of HIV-1 infectivity that equal or exceed the potencies of current clinical IN inhibitors, while retaining greater efficacy against virus harboring major resistant mutant forms of IN. A third area of investigation concerns developing antibody-drug conjugates (ADCs) in collaboration with Dr. Christoph Rader, Scripps, Florida. This work is focused on designing and synthesizing new constructs for attaching drugs and targeting moieties to antibodies.
Selected Key Publications
- Nat Chem Biol. 7: 595-601, 2011. [ Journal Article ]
Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification.ACS Chem Biol. 7: 805-10, 2012. [ Journal Article ]
- ChemBioChem. 13: 1291-1296, 2012. [ Journal Article ]
- Biopolymers Peptide Science. 104: 663-673, 2015. [ Journal Article ]
HIV-1 integrase strand transfer inhibitors with reduced susceptibility to drug resistant mutant integrases.ACS Chemical Biology. 11: 1074-1081, 2016. [ Journal Article ]
Dr. Burke received his B.S. in Chemistry from St. Martin's College, followed by his Ph.D. degree from the University of Washington under the direction of Professor Wendel Nelson. He then studied as a Fellow of the Pharmacology Associate Research Training Program in the Laboratory of Dr. Lance Pohl, National Heart Lung and Blood Institute and subsequently under the direction of Dr. Kenner Rice as a Senior Staff Fellow of the National Institute of Diabetes, Digestive and Kidney Diseases. He briefly left the NIH to serve as Principal Chemist of Peptide Technologies Corporation before returning in 1989 as a tenured Principal Investigator in the Chemical Biology Laboratory (previously, the Laboratory of Medicinal Chemistry). In 2002 he became Head of the Bioorganic and Medicinal Chemistry Section and in 2003 he was appointed a member of the Senior Biomedical Research Service (SBRS).
|Sarah Altman B.S.||Postbaccalaureate Fellow (CRTA)|
|Ramesh Chingle Ph.D.||Postdoctoral Fellow (Visiting)|
|Pankaj Mahajan Ph.D.||Postdoctoral Fellow (Visiting)|
|Kohei Tsuji Ph.D.||Postdoctoral Fellow (Visiting)|
|Xue Zhi Zhao, Ph.D.||Staff Scientist|